Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Non Operating Income of -$969000.0 in Q1 2026, up 54.61% quarter-over-quarter from -$2.1 million in Q4 2025, and up 44.12% on a YoY basis from -$672367.3 in Q1 2025.
Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$969000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 44.12% year-over-year to -$969000.0; the TTM figure through Mar 2026 stood at -$10.0 million (down 121.57% YoY), while the FY2025 annual figure was -$10.8 million, down 133.01% from the prior year.
- Non Operating Income was -$969000.0 for Q1 2026 at Galectin Therapeutics, up from -$2.1 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $461000.0 in Q4 2024 to a low of -$4.0 million in Q3 2025.
- Historically, Non Operating Income has averaged -$1.2 million across 5 years, with a median of -$1.1 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 43500.0% in 2023, then soared 205.73% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$1000.0 in 2022, then slumped by 43500.0% to -$436000.0 in 2023, then jumped by 205.73% to $461000.0 in 2024, then slumped by 563.12% to -$2.1 million in 2025, then jumped by 54.61% to -$969000.0 in 2026.
- The last three Non Operating Income figures came in at -$969000.0 (Q1 2026), -$2.1 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | -969,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -969,000.00 |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -1.73 Mn |
| Dec 31, 2024 | 461,000.00 |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Dec 31, 2023 | -436,000.00 |
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -1.19 Mn |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -475,000.00 |
| Jun 30, 2022 | 49,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | -276,000.00 |
| Jun 30, 2021 | -256,000.00 |